BioWorld

June 6, 2003

Millennium Trimming Operations, Staff As Focus Turns To Profits

In announcing a plan to restructure its organization, Millennium Pharmaceuticals Inc. said its goal is to focus on the commercially attractive items in its pipeline and to reach profitability by 2006. (BioWorld Today) Read More

NPS, Enzon End Merger Plans After Failing To Come To Terms

Rare, Unplumbable Contortions Of Dual Sézary Syndrome Malignancy Launch Therapeutic Clinical Trials

Discovery Labs' Surfaxin Support Trial Provides Positive Early Data

Isis, Lilly Rework Agreement For Affinitak Manufacturing

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for April 17, 2026.

Man holding raised arm with illustrated overlay of nerves

Biohaven reports details on discovery of BHV-2100

BioWorld Science

Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...

New GABA(B) receptor PAMs revealed in Addex Pharma patents

BioWorld Science

Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...

Elderly woman holding illustration of brain with missing puzzle piece

Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

BioWorld

The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...

Novel caspase-2 inhibitor shows in vivo neuroprotective effects

BioWorld Science

Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...